- Home
- MCRB vs IGA Comparison
MCRB vs IGA Comparison
Compare MCRB & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- IGA
- Stock Information
- Founded
- MCRB 2010
- IGA 2005
- Country
- MCRB United States
- IGA United States
- Employees
- MCRB N/A
- IGA N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- IGA Investment Managers
- Sector
- MCRB Health Care
- IGA Finance
- Exchange
- MCRB Nasdaq
- IGA Nasdaq
- Market Cap
- MCRB 165.3M
- IGA 151.6M
- IPO Year
- MCRB 2015
- IGA N/A
- Fundamental
- Price
- MCRB $15.91
- IGA $9.98
- Analyst Decision
- MCRB Hold
- IGA
- Analyst Count
- MCRB 4
- IGA 0
- Target Price
- MCRB $73.67
- IGA N/A
- AVG Volume (30 Days)
- MCRB 245.4K
- IGA 42.3K
- Earning Date
- MCRB 11-12-2025
- IGA 01-01-0001
- Dividend Yield
- MCRB N/A
- IGA 8.93%
- EPS Growth
- MCRB N/A
- IGA N/A
- EPS
- MCRB 10.22
- IGA N/A
- Revenue
- MCRB N/A
- IGA N/A
- Revenue This Year
- MCRB N/A
- IGA N/A
- Revenue Next Year
- MCRB N/A
- IGA N/A
- P/E Ratio
- MCRB $1.62
- IGA N/A
- Revenue Growth
- MCRB N/A
- IGA N/A
- 52 Week Low
- MCRB $6.53
- IGA $7.77
- 52 Week High
- MCRB $24.67
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- MCRB 44.26
- IGA 60.50
- Support Level
- MCRB $17.00
- IGA $9.83
- Resistance Level
- MCRB $24.67
- IGA $9.95
- Average True Range (ATR)
- MCRB 2.01
- IGA 0.09
- MACD
- MCRB -0.50
- IGA 0.00
- Stochastic Oscillator
- MCRB 15.94
- IGA 85.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.